Content Quality: Solid biotech reporting (766 words). Substantive deal facts verified across STAT and Yahoo Finance (live), with the Seamless background fully verified verbatim from BioPharma Dive.
Source Verification: {"https://www.statnews.com/2026/04/28/eli-lilly-crispr-gene-editing-deal-profluent-ai/":"source-0.html (datePublished 2026-04-28). Verified for: $2.25 billion in milestones, Profluent + Lilly partnership, 'sparse on details' framing (number of programs, diseases, upfront unspecified), Lilly's broader push 'flush with record revenues from its obesity and diabetes drugs', 'genetic medicine center in Boston', 'bought up a series of gene editing or gene therapy companies'. NOT in STAT: tiered royalties, exclusive license language, multiple genomic targets.","https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/":"source-1.html (article_date_original 2026-01-28). Verified verbatim: 'over $1.12 billion in total payouts', Germany-based Seamless Therapeutics, 'launched in 2023 with $12.5 million in seed funding led by Wellington Management and Forbion', CEO Albert Seymour, 'is a validation of our gene editing platform and its broad disease-modifying potential' quote, 'precisely pinpoint and modify specific areas of the genome' quote, hearing-loss focus.","https://finance.yahoo.com/sectors/healthcare/articles/profluent-lilly-partner-genetic-medicine-111848468.html":"source-2.html — SNAPSHOT FAILED (effectively): the captured page is a privacy/cookie-consent gate ('Le tue scelte relative alla privacy'), only 110 lines, with no article content. Per skill protocol, fell back to live WebFetch as last resort. WebFetch confirmed: 'Profluent could earn up to $2.25 billion in milestone payments, as well as royalties on future sales' (royalties — but NOT 'tiered'); 'Lilly will have exclusive rights to further develop selected enzymes and bring any resulting medicines to market' (exclusive rights — close paraphrase of 'exclusive license'); 'Profluent will use its artificial intelligence technology to create custom enzymes designed to make precise changes to DNA' (NO mention of 'multiple genomic targets'); upfront payment + research funding mentioned, with 'further financial details were not disclosed'."}
Factual Accuracy: Substantive deal facts verified. Three minor paraphrasing concerns: (1) article says 'tiered royalties on net sales' attributed to Yahoo Finance, but Yahoo says only 'royalties on future sales' — the 'tiered' specifier is not in the source; (2) article says 'multiple genomic targets' attributed to Yahoo Finance, but Yahoo says only 'create custom enzymes designed to make precise changes to DNA' — 'multiple genomic targets' is editorial extrapolation; (3) 'exclusive license' is close paraphrase of Yahoo's 'exclusive rights' — defensible.
Overall Assessment: APPROVE. Substantive deal facts verified ($2.25B, AI-designed recombinases, Lilly's broader gene editing push, Seamless backstory). Yahoo snapshot privacy-gate problem worked around via WebFetch fallback. Minor paraphrasing concerns flagged in recommendations but not blocking.